Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
89Zr-DFO-MSTP2109A
- Development stage
- Phase 2
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
89Zr-DFO-MSTP2109A is a radiolabeled humanized IgG1 monoclonal antibody targeting the Six Transmembrane Epithelial Antigen of the Prostate 1 (STEAP1), a cell surface protein highly expressed in prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC). The antibody (MSTP2109A) is conjugated with desferrioxamine (DFO), which chelates the positron-emitting radioisotope zirconium-89 (^89Zr^). This radioimmunoconjugate enables PET imaging to detect and localize STEAP1-expressing tumors. Developed as a diagnostic agent, it has demonstrated favorable biodistribution, high tumor uptake, and safety in Phase 1/2 clinical trials for mCRPC. The agent is being explored as a companion diagnostic for STEAP1-targeted therapies[1][3][5][6].
- Other names
- zirconium Zr 89-DFO-MSTP2109A
02
Targets
STEAP1 (Six-transmembrane epithelial antigen of prostate 1)
Beyond the preview
Go deeper on 89Zr-DFO-MSTP2109A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 89Zr-DFO-MSTP2109A.